keyword
MENU ▼
Read by QxMD icon Read
search

Indolent lymphoma

keyword
https://www.readbyqxmd.com/read/28633365/phase-ii-study-of-copanlisib-a-pi3k-inhibitor-in-relapsed-or-refractory-indolent-or-aggressive-lymphoma
#1
M Dreyling, F Morschhauser, K Bouabdallah, D Bron, D Cunningham, S E Assouline, G Verhoef, K Linton, C Thieblemont, U Vitolo, F Hiemeyer, M Giurescu, J Garcia-Vargas, I Gorbatchevsky, L Liu, K Koechert, C Peña, M Neves, B H Childs, P L Zinzani
Background: Copanlisib is a pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor with predominant activity against the α- and δ- isoforms. Patients and methods: This phase II study evaluated the response rate of copanlisib administered intravenously on days 1, 8, and 15 of a 28-day cycle, in patients with indolent or aggressive malignant lymphoma. Archival tumor tissues were used for immunohistochemistry, gene-expression profiling, and mutation analysis...
June 14, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28633038/hematopoietic-cell-transplantation-for-diffuse-large-b-cell-and-follicular-lymphoma-current-controversies-and-advances
#2
REVIEW
Narendranath Epperla, Mehdi Hamadani
Non-Hodgkin's lymphoma (NHL) constitutes a collection of lymphoproliferative disorders with diverse biologic, histologic, and clinical features. With a better understanding of the molecular pathogenesis, recently there have been major advances in the treatment of NHLs including addition of novel monoclonal antibodies, targeted therapies, and immune activators to the therapy armamentarium. Despite these remarkable developments, autologous hematopoietic cell transplantation (auto-HCT) remains not only a standard-of-care curative option for aggressive NHL but also an important therapeutic option for indolent NHL...
June 13, 2017: Hematology/oncology and Stem Cell Therapy
https://www.readbyqxmd.com/read/28628883/pros-and-cons-of-rituximab-maintenance-in-follicular-lymphoma
#3
REVIEW
Lu Zhang, Michele Ghielmini, Bruce D Cheson, Chaitra Ujjani
Follicular lymphoma (FL) is the most prevalent indolent non-Hodgkin lymphoma. Most patients present with advanced disease and are incurable with current therapy. The approval of rituximab has revolutionized the treatment of follicular lymphoma when administered in the induction setting for high-tumor burden disease, but the use of rituximab as a maintenance therapy (MR) continues to be a point of controversy. In this article, we review the main data and arguments in favor and against MR in FL. In summary, most studies have demonstrated a significant benefit in progression-free or event-free survival in this notoriously recurrent disease; however, long-term outcomes could not consistently demonstrate to be improved with this intervention...
June 16, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/28600333/how-i-treat-double-hit-lymphoma
#4
Jonathan W Friedberg
The 2016 revision of the WHO classification for lymphoma classification has included a new category of lymphoma, separate from diffuse large B-cell lymphoma termed High grade B-cell lymphoma with translocations involving myc and bcl-2 or bcl-6 These lymphomas, which occur in less than 10% of cases of diffuse large B-cell lymphoma, have been referred to as "double hit" lymphomas (or triple hit lymphomas if all three rearrangements are present). It is important to differentiate these lymphomas from the larger group of "double expressor" lymphomas which have increased expression of MYC and BCL-2 and/or BCL-6 by immunohistochemistry, using variable cut-off percentages to define positivity...
June 9, 2017: Blood
https://www.readbyqxmd.com/read/28597151/outcomes-and-prognostic-factors-for-relapsed-or-refractory-lymphoma-patients-in-phase-i-clinical-trials
#5
Jean-Marie Michot, Lina Benajiba, Laura Faivre, Capucine Baldini, Lelia Haddag, Clement Bonnet, Christophe Massard, Frederic Bigot, Camille Bigenwald, Benjamin Verret, Zoé A P Thomas, Andrea Varga, Anas Gazzah, Antoine Hollebecque, David Ghez, Julien Lazarovici, Rastilav Balheda, Aurore Jeanson, Sophie Postel-Vinay, Alina Danu, Jean-Charles Soria, Xavier Paoletti, Vincent Ribrag
Background Although safety and prognostic factors for overall survival (OS) have been extensively studied in Phase I clinical trials on patients with solid tumours, data on lymphoma trials are scarce. Here, we investigated safety, outcomes and prognostic factors in relapsed or refractory lymphoma patients included in a series of Phase I trials. Method and patients All consecutive adult patients with recurrent/refractory lymphoma enrolled in 26 Phase I trials at a single cancer centre in France between January 2008 and June 2016 were retrospectively assessed...
June 9, 2017: Investigational New Drugs
https://www.readbyqxmd.com/read/28594662/patient-derived-tumor-xenografts-of-lymphoproliferative-disorders-are-they-surrogates-for-the-human-disease
#6
Marco Pizzi, Giorgio Inghirami
PURPOSE OF REVIEW: Patient-derived tumor xenografts (PDTXs) have emerged as powerful platforms in medical oncology. A plethora of PDTXs were generated to study solid cancers, but limited data are as yet available on hematological diseases. The aim of this review is to describe the state of art of lymphoma PDTXs, discussing future directions for the development of integrated/personalized cancer programs. RECENT FINDINGS: In the last decades, several PDTXs of lymphoproliferative disorders have been produced...
July 2017: Current Opinion in Hematology
https://www.readbyqxmd.com/read/28592744/treatment-advances-and-prognosis-for-patients-with-adult-t-cell-leukemia-lymphoma
#7
Hiroo Katsuya, Kenji Ishitsuka
A classification for adult T-cell leukemia-lymphoma (ATL) based on clinical features was proposed in 1991: acute, lymphoma, chronic, and smoldering types, and their median survival times (MSTs) were reported to be 6.2, 10.2, 24.3 months, and not reached, respectively. Several new therapies for ATL have since been developed, i.e. dose-intensity multi-agent chemotherapies, allogeneic hematopoietic stem cell transplantation (allo-HSCT), monoclonal antibodies, and anti-viral therapy. The monoclonal antibody to CCR4, mogamulizumab, clearly improved response rates in patients with treatment-naïve and relapsed aggressive ATL, and has the potential to provide a survival advantage...
June 8, 2017: Journal of Clinical and Experimental Hematopathology: JCEH
https://www.readbyqxmd.com/read/28591426/chemotherapy-free-treatment-of-indolent-lymphoma
#8
Carla Casulo, Jonathan W Friedberg
No abstract text is available yet for this article.
June 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28577652/splenic-marginal-zone-lymphoma-a-literature-review-of-diagnostic-and-therapeutic-challenges
#9
Tayse Silva Dos Santos, Renato Sampaio Tavares, Danielle Leão Cordeiro de Farias
Splenic marginal zone lymphoma (SMZL) is a low-grade B-cell non-Hodgkin's lymphoma characterized by massive splenomegaly, moderate lymphocytosis with or without villous lymphocytes, rare involvement of peripheral lymph nodes and indolent clinical course. As a rare disease, with no randomized prospective trials, there is no standard of care for SMZL so far. Splenectomy has been done for many years as an attempt to control disease, but nowadays it has not been encouraged as first line because of new advances in therapy as rituximab, that are as effective with minimal toxicity...
April 2017: Revista Brasileira de Hematologia e Hemoterapia
https://www.readbyqxmd.com/read/28574809/testicular-seminoma-and-its-mimics
#10
Jamie Marko, Darcy J Wolfman, Alex L Aubin, Isabell A Sesterhenn
Testicular seminoma is the most common malignant tumor of the testis. It classically manifests as a painless mass. Radiologic evaluation with high-frequency ultrasonography (US) is critical for diagnosis. Seminomas are usually homogeneously hypoechoic masses at US. In challenging cases, magnetic resonance (MR) imaging may help confirm that a mass is intratesticular and provide data for local staging. Computed tomography (CT) provides valuable information for staging, including the presence and size of retroperitoneal lymph nodes...
June 2, 2017: Radiographics: a Review Publication of the Radiological Society of North America, Inc
https://www.readbyqxmd.com/read/28573510/b-cell-lymphomas-with-discordance-between-pathological-features-and-clinical-behavior
#11
Laurence de Leval, Christiane Copie-Bergman, Andreas Rosenwald, Lisa Rimsza, Stefania Pittaluga, Bettina Bisig, Stefan Dirnhofer, Fabio Facchetti, Stefano Pileri, Falko Fend, Andrew Wotherspoon
B-cell lymphomas encompass a large number of disease entities clinically ranging from indolent to aggressive. The defining pathological features usually predict clinical course, with small and large B-cell lymphomas correlating to low-grade vs high-grade features, but discordant situations may be encountered. Two sessions of the workshop of the XVIII meeting of the European Association for Haematopathology (EAHP) held in Basel in 2016 addressed this topic. One session illustrated various facets of "aggressiveness" in indolent lymphomas, either peculiar clinical manifestations, cytological variants, or unusual genetic features, as well as several examples of progression or transformation to a more aggressive disease...
June 1, 2017: Virchows Archiv: An International Journal of Pathology
https://www.readbyqxmd.com/read/28566677/high-grade-transformation-in-a-splenic-marginal-zone-lymphoma-with-a-cerebral-manifestation
#12
Xiaoning Gao, Jie Li, Ji Lin, Daihong Liu, Li Yu, Quanshun Wang
BACKGROUND Splenic marginal zone lymphomas (SMZLs) are generally uncommon, indolent lymphomas that typically affect older adults, but the development of the transformation to high-grade lymphoma may occur in a small proportion of patients and represents a rare event with blastic cell infiltration in the lymph nodes and bone marrow. CASE REPORT Here, we present a young adult patient who was diagnosed with a SMZL and developed a high-grade transformation to diffuse large B cell lymphoma (DLBCL) with central nervous system involvement...
June 1, 2017: American Journal of Case Reports
https://www.readbyqxmd.com/read/28561902/safety-and-pharmacokinetics-of-bendamustine-rapid-infusion-formulation
#13
Eric M Cheung, William J Edenfield, Bassam Mattar, Stephen P Anthony, Peter J Mutch, Brian Chanas, Mark Smith, Adrian Hepner
Bendamustine hydrochloride (BDM) is approved in the United States to treat chronic lymphocytic leukemia and relapsed indolent B-cell non-Hodgkin lymphoma. The first formulation marketed in the United States (original BDM) was a lyophilized product requiring reconstitution prior to dilution to the final admixture. A liquid formulation of BDM was subsequently introduced that did not require reconstitution before dilution. Both formulations are administered as a 500 mL admixture with a recommended infusion time of 30 or 60 minutes for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma, respectively...
May 31, 2017: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28554945/genetic-background-and-evolution-of-relapses-in-aggressive-b-cell-lymphomas
#14
Darius Juskevicius, Stephan Dirnhofer, Alexandar Tzankov
Relapses of aggressive B-cell lymphomas pose a higher risk to the affected patients due to potential treatment resistance and usually more aggressive tumor growth. Recent advances, such as targeting Bruton tyrosine kinase showed promising results in small number of cases, however treatment for the majority of patients remains challenging and outcomes are generally poor. Recently, a number of studies were published, which utilized state-of-the-art genomic technologies in an attempt to better understand tumor genome evolution during relapse and identify relapse-specific genetic alterations...
May 29, 2017: Haematologica
https://www.readbyqxmd.com/read/28544534/time-to-event-analysis-of-polatuzumab-vedotin-induced-peripheral-neuropathy-to-assist-in-the-comparison-of-clinical-dosing-regimens
#15
D Lu, W R Gillespie, S Girish, P Agarwal, C Li, J Hirata, Y-W Chu, M Kagedal, L Leon, V Maiya, J Y Jin
Polatuzumab vedotin, an antibody-drug conjugate containing monomethyl auristatin E, was associated with an incidence of grade ≥2 peripheral neuropathy (PN) of 55-72% in patients with indolent non-Hodgkin lymphoma in a phase II study, when dosed 1.8-2.4 mg/kg every 3 weeks until progression or for a maximum of 17 cycles. To quantify the correlation of conjugate exposure and treatment duration with PN risk, a time-to-event model was developed using data from phase I and II studies. The model suggested that PN risk increased with conjugate exposure and treatment cycles, and a trend for increased risk with body weight and albumin concentration...
May 23, 2017: CPT: Pharmacometrics & Systems Pharmacology
https://www.readbyqxmd.com/read/28534374/rituximab-in-the-therapy-of-stage-iii-and-iv-follicular-lymphoma-results-of-the-reflect-1-study-of-the-serbian-lymphoma-group
#16
Stevan Popovic, Darjana Jovanovic, Biljana Mihaljevic, Nebojsa Andjelkovic, Goran Marjanovic, Dragomir Marisavljevic, Nada Vlaisavljevic, Lazar Popovic, Svetlana Salma, Danijela Agic, Rajko Milosevic, Mihajlo Smiljanic, Snezana Sretenović, Predrag Djurdjević, Olivera Markovic, Jelena Hajder, Nenad Govedarovic
PURPOSE: Follicular lymphoma (FL) is an indolent lymphoma that responds well to rituximab+chemotherapy. We evaluated the prognosis and efficacy of immunochemotherapy in patients with previously untreated, advanced FL. METHODS: REFLECT 1 is a multicentre, prospective study of 99 patients with previously untreated FL stage III-IV. All patients were treated with rituximab+chemotherapy x 6 cycles, plus 2 cycles of rituximab monotherapy. Clinical assessment was performed at baseline, after completion of the first 6 cycles of therapy and every 3 months from the end of immunochemotherapy to the end of the study period...
March 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/28533834/-splenic-marginal-zone-lymphoma
#17
Sinaa Mohamed
Splenic marginal zone lymphoma (SMZL) is a rare B-cell lymphoma, well defined according to the 2016 WHO classification of tumors of the hematopoietic tissue, which can raise diagnostic problems. We report the case of a 72-year old patient, hospitalised for exploration of a massive splenomegaly confirmed by computed tomography (CT). Laboratory tests were normal. The patient underwent splenectomy. Microscopic examination of the surgical specimen showed widespread lymphomatous proliferation in small cells associated with CD20 marker...
2017: Pan African Medical Journal
https://www.readbyqxmd.com/read/28531181/weekly-versus-biweekly-bortezomib-given-in-patients-with-indolent-non-hodgkin-lymphoma-a-meta-analysis
#18
Ting Yuan, Feng Zhang, Qing-Min Yao, Yan-Xia Liu, Xiao-Juan Zhu, Xin Wang
BACKGROUND: Bortezomib is recently studied as a novel agent in indolent lymphoma. The optimal schedule of bortezomib used in indolent lymphoma is still uncertain. METHODS: We did a systematic review and meta-analysis of the clinical trials comparing the efficacy and toxicity of the weekly and biweekly schedules of bortezomib in patients with indolent lymphoma. We searched Pubmed, Cochrane Library and Emabase from inception to July 29, 2016. The primary outcome was the overall response rate including the complete response rate and the partial response rate...
2017: PloS One
https://www.readbyqxmd.com/read/28523163/a-single-center-experience-rituximab-plus-cladribine-is-an-effective-and-safe-first-line-therapy-for-unresectable-bronchial-associated-lymphoid-tissue-lymphoma
#19
Zheng Wei, Jing Li, Zhixiang Cheng, Ling Yuan, Peng Liu
BACKGROUND: Bronchial-associated lymphoid tissue (BALT) lymphoma is a relatively rare form of B-cell non-Hodgkin lymphoma (B-NHL). To date, the standard systemic treatment for this disease is still under debate, and few data are accessible for newly diagnosed unresectable BALT lymphoma presented with advanced disease. The combination of rituximab (R) and cladribine (2-CdA) has shown some activity in indolent B-NHL, but its usage has not been tested in disseminated BALT lymphoma so far...
April 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28516439/reassessment-of-anti-cd20-therapy-in-lymphoid-malignancies-impact-limitations-and-new-directions
#20
REVIEW
Patrick M Reagan, Jonathan W Friedberg
The addition of anti-CD20 monoclonal antibodies to the treatment of B-cell malignancies has dramatically affected the field as well as the lives of patients. Rituximab in particular has been combined safely with conventional chemotherapy and has resulted in improved overall survival in major histologic subtypes of B-cell lymphoma and chronic lymphocytic leukemia. It is incorporated into the standard initial treatment of nearly all of these diseases. Novel anti-CD20 antibodies are currently under development...
May 15, 2017: Oncology (Williston Park, NY)
keyword
keyword
99818
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"